1. Introduction {#s0005}
===============

Amorphous Solid Dispersions (ASDs) are widely used bioavailability enhancing formulations for drugs with low solubility and/or slow dissolution rate in gastrointestinal fluids ([@bb0235]). ASDs comprise an amorphous drug dispersed within a matrix. The amorphous drug provides greater aqueous solubility to aid absorption relative to the crystalline form. The matrix is typically a polymer that acts to stabilize the drug in the amorphous state during storage and in gastrointestinal (GI) fluids ([@bb0030]; [@bb0110]; [@bb0210]).

Drugs with a low glass transition temperature (T~g~) and a high ratio of melting point (T~m~) to T~g~ (T~m~/T~g~ (K/K)) tend to recrystallize due to an overall high driving force and low kinetic barrier to crystallization ([@bb0065]). A drug with a high T~m~ requires high thermal energy to break the crystal lattice, which generally results in a high energy difference between the crystalline and amorphous forms of the drug. This high energy difference can lead to a high thermodynamic driving force for the drug to convert to the lower energy crystalline state. A low T~g~ indicates a high degree of molecular mobility and therefore a low kinetic barrier to crystallization.

Low T~g~, rapidly crystallizing drugs often need a high percentage of dispersion polymer in the ASD to adequately stabilize the drug in the solid state and in solution ([@bb0020])^,^([@bb0215]; [@bb0230]). For example, a dispersion polymer loading of 75% is common, with dispersion polymer loadings of up to 90--95% being reported. The high percentage of dispersion polymer in the ASD not only results in low drug loading but can also cause poor disintegration. ASDs compressed into tablets may disintegrate slowly when the ASD loading in the tablet exceeds 30--70% ([@bb0055])^,^ ([@bb0005]). Poor disintegration is particularly common for neutral polymers, such as polyvinylpyrrolidone (PVP, e.g. K30 grade), polyvinylpyrrolidone vinyl acetate (PVP VA, i.e. VA 64 grade) and hydroxypropyl methylcellulose (HPMC, e.g. E3 grade) that are soluble across the GI pH range. These polymers hydrate immediately upon introduction into the stomach, resulting in a higher propensity to gel compared to polymers such as Eudragit L100 and HPMCAS that are nearly insoluble at low gastric pH ([@bb0075]). Due to the tendency for ASDs to gel, a relatively high fraction of excipients must be added to the tablet formulation to facilitate more rapid disintegration. The addition of certain types of inorganic salts to the formulation has been shown to decrease gelling and improve drug release from ASD tablets ([@bb0200]) ([@bb0090]) ([@bb0100]). Due to the combined factors of low drug loading in the ASD, and low ASD loading in the tablet, a high tablet mass or multiple tablet units (i.e. high tablet burden) is often required to deliver the prescribed dose.

The acceptable tablet size and number of units depends upon several criteria. For example, dose, indication, age of the targeted population (e.g., adult, pediatric, geriatric), healthy or disease state, desired market image and drug product life cycle all need to be considered. For high dose drugs, tablet burden may be a significant issue. According to Pharmacircle, 24% of all prescription drug products marketed worldwide, including amorphous and non-amorphous drug substances, have doses of 200 mg or greater ([@bb0165]). Of 22 FDA-approved ASD drug products surveyed according to the maximum dosage strength, more than 50% have maximum dosage strengths greater than 100 mg ([@bb0190] (in press)). In some cases, accommodating a 100 mg dosage strength for an ASD drug product could require a high tablet mass, which could result in poor patient compliance or be untenable for pediatric and geriatric populations. The tablet mass required to achieve a given dose is determined by the drug loading in the ASD and the ASD loading in the tablet. Typical ASD drug loadings range from 10--40%, whereas ASD loadings in the tablet often range from 40--80%. Assuming these ranges, a total tablet mass of 300--2500 mg would be required to achieve a 100 mg active dose in a single dosage unit. For example, a 25% active ASD with a 50% ASD loading in the tablet would result in a total tablet mass of 800 mg to achieve a 100 mg active dose. The 100 mg dosage strength of the commercial spray dried ASD tablet, Intelence®, has an 800 mg total mass ([@bb0245]). ASD drug products indicated for infections are likely to require strategies for limiting tablet burden, as 56% of current drug products indicated for infections have doses of 200 mg or greater ([@bb0165]).

To address high tablet burden, a strategy was developed to maximize the percentage of drug in a rapidly disintegrating ASD dosage form for low T~g~, rapidly crystallizing drugs. In this approach, a drug is spray dried with a high T~g~ polymer to facilitate high drug loading in the ASD ([@bb0015]). To extend drug supersaturation in solution, a concentration sustaining polymer (CSP) is granulated with the ASD prior to tableting ([@bb0155]) ([@bb0250]). In this study, the enteric polymer, poly(methyl methacrylate-*co*-methacrylic acid) (1:1) (Eudragit® L100, Evonik Industries, Essen, Germany) (T~g~ = 187 °C) Eudragit® L100 was selected as the dispersion polymer due to its high T~g~, which is 30--70 °C higher than common dispersion polymers such as HPMCAS, PVP, PVP VA and HPMC ([@bb0180]). Hydroxypropyl methylcellulose acetate succinate (HPMCAS) (T~g~ = 119 °C) H grade was chosen as the CSP. HPMCAS is a particularly effective CSP due its amphiphilic nature when ionized at small intestinal pH. At pH \> \~5, hydrophobic regions of HPMCAS can interact with hydrophobic drugs, and carboxylate groups can interact with the aqueous phase at the drug-water interface to inhibit crystal nucleation and growth ([@bb0135]) ([@bb0170]) ([@bb0065]). The H grade of HPMCAS H was chosen for this study since it has the highest percentage of hydrophobic acetyl substitution of the standard HPMCAS grades, allowing it to interact most effectively with hydrophobic drugs. Compared to HPMCAS, Eudragit L100 is typically a less effective CSP. Potential factors contributing to its relative ineffectiveness as a CSP include its hydrophilicity and lack of branches or bulky groups for forming favorable polymer-drug interactions ([@bb0135]) ([@bb0095]).

This work describes use of the HLDF architecture to reduce tablet mass by 40% compared to a typical approach. In a typical ASD formulation the dispersion polymer(s) enables both solid-state physical stability and dissolution rate and/or concentration sustainment in GI fluids. In contrast, the HLDF architecture combines two different polymers, one inside and one outside the ASD to achieve physical stability and concentration sustainment. HLDF and typical 'benchmark' ASDs were assessed for physical stability and tablets were assessed for *in vitro* dissolution performance. Manufacturability of the HLDF tablets was assessed by characterizing tablet attributes after manufacturing at the kilogram scale and assessing flow and mechanical properties of the final blend. Physical stability and *in vitro* performance were found to be comparable for the HLDF and benchmark formulation approaches, and excellent manufacturability was demonstrated for the HLDF architecture.

2. Materials and methods {#s0010}
========================

2.1. Materials {#s0015}
--------------

### 2.1.1. Selection of model drug {#s0020}

Erlotinib is a weak base with poor aqueous solubility and moderate lipophilicity, placing it into the provisional Biopharmaceutics Classification System (BCS) category 2 ([@bb0010]; [@bb0050]; [@bb0220]). Refer to [Fig. 1](#f0005){ref-type="fig"} and [Table 1](#t0005){ref-type="table"} for the structure and physical properties, respectively. Erlotinib was chosen as a model drug due to its low T~g~ (42 °C) and tendency to recrystallize both in the solid state and in solution at intestinal pH, as indicated by its high T~m~/T~g~ (1.4 K/K). These attributes made it an ideal candidate for demonstrating the HLDF architecture from a physical property perspective. For example, polymer stabilization is required both in the solid state and in solution to achieve good physical stability and *in vitro* dissolution performance.Fig. 1Erlotinib structure.Fig. 1Table 1Erlotinib physicochemical properties.Table 1PropertyValueMolecular mass (g/mol)393.4pK~a~ (basic)5.3[a](#tf0005){ref-type="table-fn"}Log P2.75[a](#tf0005){ref-type="table-fn"}Log D (pH 2)0.66[a](#tf0005){ref-type="table-fn"}T~m~ (°C)157[b](#tf0010){ref-type="table-fn"}T~g~ (°C)42 [b](#tf0010){ref-type="table-fn"}T~m~/T~g~1.4Crystalline equilibrium solubility at pH 2 (μg/mL)1534[c](#tf0015){ref-type="table-fn"}Crystalline equilibrium solubility pH 6.5 (μg/mL)3[d](#tf0020){ref-type="table-fn"}Crystalline equilibrium solubility pH 6.5 + 0.5% (*w*/w) FaSSIF powder (μg/mL)8.6[d](#tf0020){ref-type="table-fn"}Crystalline equilibrium solubility pH 6.5 + 1% (*w*/w) FaSSIF powder (μg/mL)19.7[d](#tf0020){ref-type="table-fn"}[^1][^2][^3][^4]

To improve low oral bioavailability of the poorly soluble free base, erlotinib is marketed as a hydrochloride salt under the tradename Tarceva®. Common dosages of erlotinib are 100 mg/day (pancreatic cancer) and 150 mg/day (non-small cell lung cancer). It is prescribed fasted due to a positive food effect. In addition, the FDA label recommends avoidance of concomitant use with Proton Pump Inhibitors (PPIs) and modification of the dosing schedule when using H-2 receptor antagonists and antacids due to decreased plasma exposure ([@bb0115]) ([@bb0145]). The 100 mg tablet has a reported absolute bioavailability of 76% ([@bb0175]). The 150 mg Tarceva tablet has an absolute bioavailability of 59% ([@bb0070]). Improving Tarceva, for example, by reducing dosage form size, improving bioavailability or mitigating the food or PPI effect was not a goal of this study.

### 2.1.2. Material sourcing {#s0025}

Erlotinib free base (\> 99% purity) (CAS 183321-74-6) was purchased from LC Laboratories (Woburn, MA, USA) to support drug characterization and lab scale spray drying and from BOC Sciences (Shirley, NY, USA) to support clinical scale spray drying. HPMCAS-H AQOAT® HF was purchased from Shin-Etsu Chemical Co., Ltd. (Tokyo, Japan). Avicel® PH-101 microcrystalline cellulose was purchased from FMC Corporation (Philadelphia, PA, USA). Foremost® Lactose 310 was purchased from Foremost Farms (Baraboo, WI, USA). Ac-Di-Sol® croscarmellose sodium was purchased from FMC Corporation (Philadelphia, PA, USA). Cab-O-Sil® fumed silica was purchased from Cabot Corporation (Alpharetta, GA, USA). Magnesium stearate was purchased from Macron Fine Chemicals/Avantor (Radnor, PA, USA). Methanol, ethanol, acetonitrile, and acetone were purchased from Honeywell International Inc. (Morris Plains, New Jersey, USA). Hydrochloric acid (HCl), sodium phosphate, potassium phosphate, and sodium chloride were purchased from Sigma Aldrich Chemical Company (St. Louis, Missouri, USA). Fasted state simulated intestinal fluid (FaSSIF) powder purchased from [Biorelevant.com](http://Biorelevant.com){#ir0005} Ltd. (London, United Kingdom).

2.2. HLDF formulation development approach {#s0030}
------------------------------------------

The HLDF architecture is designed to minimize tablet mass for ASDs, while still maintaining good manufacturability, stability and bioperformance. The tablet mass for a given unit dose is determined by the drug loading in the ASD and the ASD loading in the tablet. In this study, the drug loading in the ASD was taken as the highest loading found to be physically stable after storage at 40 °C/75% relative humidity (RH) for 4 weeks as described in [Section 3.2](#s0150){ref-type="sec"}. Since a rapidly disintegrating tablet was targeted for this study to facilitate rapid dispersal of ASD particles, the ASD loading in the tablet was taken as the maximum loading resulting in rapid disintegration (i.e. \<3 min) that also provided adequate downstream manufacturability.

The above methodology allowed for tablet size to be minimized for both the HLDF and benchmark formulation architectures. An HLDF tablet with a 350-mg total mass and a drug loading of 29% was manufactured using a 65/35 (% w/w) erlotinib/Eudragit L100 ASD granulated with HPMCAS-H (1:1 HPMCAS-H/erlotinib) as the CSP on kilogram scale processing equipment. A traditional, benchmark ASD tablet with a 575-mg total mass and a drug loading of 18%, comprising a 35/65 erlotinib/HPMCAS-H ASD was used as a positive control. A negative control tablet was also created comprising a 65/35 (% w/w) erlotinib/Eudragit L100 ASD, which was not granulated with HPMCAS. See [Table 2](#t0010){ref-type="table"} for a summary of tablet compositions. See Table A1 (appendix section A.1) for detailed tablet compositions.Table 2Tablet formulation compositions.Table 2Tablet formulation [a](#tf0025){ref-type="table-fn"}% Drug loading in tabletTablet mass (mg)ASD composition% ASD in tablet% External HPMCAS-H in tablet% Tableting excipients in tablet [b](#tf0030){ref-type="table-fn"}HLDF2935065/35 erlotinib/Eudragit L100442927Benchmark1857535/65 erlotinib/HPMCAS-H50050Negative control2935065/35 erlotinib/Eudragit L10044056[^5][^6]

2.3. ASD manufacturing {#s0035}
----------------------

### 2.3.1. Lab-scale spray drying {#s0040}

Small scale studies were supported by ASDs made on a lab-scale spray dryer. ASDs were manufactured at drug loadings of 25, 50, 60, 65 and 75% in Eudragit L100, and 25, 35, 50 and 60% in HPMCAS-H. Spray solutions were prepared by dissolving erlotinib and a dispersion polymer (Eudragit L100 or HPMCAS-H) in methanol at the desired ratio of erlotinib to polymer, while maintaining a solids loading of 3% (w/w). A 3% (w/w) solids loading was the maximum loading achievable for the high loaded ASDs based upon the erlotinib solubility in methanol (2.2% (w/w) at room temperature, measured in house using thermogravimetric analysis, data not shown). Solutions were spray dried with an outlet temperature of 45--50 °C and inlet temperature of 150--160 °C on a customized spray dryer (suitable for batch sizes from 0.5--200 g) capable of drying gas flow rates of up to 35 kg/h using a pressure swirl Schlick model 121, size 2.0 spray nozzle (Düsen-Schlick GmbH, Untersiemau, Germany). Spray dried ASDs were placed in a Gruenberg Benchtop Lab Dryer (Thermal Product Solutions, New Columbia, PA) for \>18 h at 35--40 °C to remove residual solvent (RH was not controlled).

### 2.3.2. Clinical-scale spray drying {#s0045}

Clinical-scale spray drying was performed to generate 65/35 erlotinib/Eudragit L100 ASD for kilogram-scale HLDF tablet manufacturing. Spray solutions were prepared by dissolving erlotinib and Eudragit L100 in methanol at ratio of 65/35 at a solids loading of 3% (w/w). The solids loading was limited by the solubility of erlotinib in methanol (2.2% w/w). Solutions were spray dried with an outlet temperature of 45 °C and inlet temperature of 150--160 °C on a customized clinical-scale spray dryer capable of drying gas flow rates of up to 150 kg/h using a pressure swirl SK-80-16 spray nozzle (Spraying Systems, USA). These spray drying processing parameters were selected to de-risk formation of filament particles that sometimes occurs with Eudragit L100 ([@bb0180]). The batch size was 2.5 kg of ASD. After the spray drying process, spray dried ASDs were placed in an ES2000--12 environmental chamber (Bahnson Environmental Specialties, NC, USA) for \>14 h at 40 °C and 15% RH to remove residual solvent.

2.4. ASD, drug and polymer characterization {#s0050}
-------------------------------------------

### 2.4.1. Erlotinib crystalline solubility {#s0055}

The crystalline solubility of erlotinib was measured in 1) pH 6.5, 67 mM phosphate, 2) pH 6.5, 67 mM phosphate containing 0.5% (w/w) FaSSIF powder (FaSSIF, Biorelevant Inc), and 3) pH 6.5, 67 mM phosphate containing 1% (w/w) FaSSIF powder. These media were chosen to bracket compositions present in the *in vitro* dissolution tests. See appendix section A.2 for methods.

### 2.4.2. Powder X-Ray Diffraction (PXRD) {#s0060}

To assess crystallinity of initial and aged samples, XRD patterns were obtained at room temperature using a Rigaku MiniFlex 600 X-Ray diffractometer operating with a copper anode (K~α1~ = 1.5060 Å; K~α2~ = 1.54439 Å) generator set at 45 kV and 15 mA, in 2-theta range 3--40° 2θ, scanned at a rate of 2.5° 2θ per minute in continuous scanning mode, and using a D/teX Ultra high speed detector.

### 2.4.3. Scanning Electron Microscopy (SEM) {#s0065}

ASDs were assessed for the presence of crystals as well as particle shape and morphology using a Hitachi SU3500 scanning electron microscope (SEM) (Hitachi High Technologies America Inc., Schaumburg, IL). Approximately 0.5 mg of sample was mounted to an aluminum stub with 2-sided carbon tape. The sample was sputter-coated (Hummer Sputtering System, Model 6.2, Anatech Ltd.) with an Au/Pd stage for 10 min at 15 mV, and studied by SEM.

### 2.4.4. Differential Scanning Calorimetry (DSC) {#s0070}

Melting point, enthalpy of fusion and T~g~ of the as-received crystalline drug and T~g~ of the spray dried ASDs were measured using a TA Instruments Q2000 modulated differential scanning calorimeter (TA Instruments-Waters L.L.C, New Castle, DE) equipped with a refrigerated cooling accessory (RCS90). The melting point and enthalpy of fusion of the as-received crystalline drug were measured on heating (10 K/min non-modulated). After heating through the melt, the molten sample was promptly removed from the furnace and quenched into liquid nitrogen (\~7200 K/min quench rate) to amorphize the sample. The T~g~ of the resulting sample was then measured on re-heating (modulated mode at a scan rate of 2.5 °C/min, modulation of ±1.5 °C/min).

To measure ASD T~g~, ASD Samples were prepared as loose powder, loaded into a Tzero pan (TA Instruments) and equilibrated at \<5% RH, 25% RH, 50% RH and/or 75%RH at ambient temperature for up to 18 h. Samples were then crimped with hermetic lids and run in modulated mode at a scan rate of 2.5 °C/min, modulation of ±1.5 °C/min, and a scan range −40 to 200 °C. A nitrogen gas flow rate of 50 ml/min was used to maintain an inert atmosphere. Unless otherwise stated, reported T~g~s are the temperatures at half height of the glass transition. The relationships between T~g~ and drug loading as well as T~g~ and relative humidity were assessed and compared between Eudragit L100 and HPMCAS-H dispersion polymers.

2.5. ASD accelerated physical stability studies {#s0075}
-----------------------------------------------

HPMCAS-H and Eudragit L100 ASDs (drug loadings of 25, 50, 60, 65 and 75% in Eudragit L100 and 25, 35, 50 and 60% in HPMCAS) were stored at elevated temperature and RH. Approximately 100 mg of each material was placed in a 4-ml glass vial. Each vial was then covered with perforated aluminum foil and transferred to a temperature/humidity-controlled oven (Model ES2000, Environmental Specialties International, lnc., Baton Rouge, LA) at 40 °C/75% RH and allowed to stand undisturbed for 1, 2 and 4 weeks. Samples were then removed from the oven and transferred to a vacuum desiccator for up to 18 h to remove water. After drying, the samples were removed from the vacuum desiccator and stored at 5 °C. Aged ASDs were analyzed for crystallinity using SEM and PXRD and thermal properties using DSC.

2.6. Tablet manufacturing and powder characterization {#s0080}
-----------------------------------------------------

### 2.6.1. Small scale manufacturing of benchmark and negative control tablets {#s0085}

The negative control tablet and benchmark tablet were made using a small scale, semi-manual manufacturing process. Briefly, the ASD and intra-granular excipients (See Table A1 in appendix section A.1) were blended and the intra-granular blend was compressed into slugs using a Manesty F3 single station tablet press (Manesty Ltd., Knowsley, England). Slugs were milled using a mortar and pestle and passed through a \#20 mesh screen to create the intra-granular blend. The intra-granular blend was blended with extra-granular excipients and lubricated. The final blend was then compressed into tablets at a target Tensile Strength (TS) of 2 MPa using the F3 press. Complete manufacturing details are included in the appendix section A.3.

### 2.6.2. Kilogram scale manufacturing to make HLDF tablets {#s0090}

HLDF tablets were manufactured at a kilogram manufacturing scale (5-kg pre-granulation blend) to demonstrate the viability of producing tablets comprising a fine particle size excipient (i.e. HPMCAS-HF) external to the ASD. Briefly, the ASD and intra-granular excipients (See Table A1 in appendix section A.1) were blended and lubricated. The intra-granular blend was roller compacted using a Gerteis MINI-PACTOR® roller compactor (Gerteis Maschinen + Processengineering AG, Jona, Switzerland). Ribbons were milled through a 1.0 mm square wire mesh screen using the Gerteis in-line mill to create the intra-granular blend. The intra-granular blend was blended with extra-granular excipients and lubricated. The final blend was compressed into tablets using a Korsch XL-100 tablet press (Korsch America, South Easton, MA). Tablets were compressed to a target TS of 2.0 MPa at a 20-rpm turret speed. Additional tablets were produced at different TS values and one additional turret speed (See Table A3 in the appendix section A.3) to assess the impact of TS and turret speed on disintegration time and friability. Complete manufacturing details are included in the appendix section A.3.

2.7. HLDF powder characterization {#s0095}
---------------------------------

Powder and flow properties including bulk density, tapped density, true density and Carr\'s Index were measured for the intragranular and final blends. Flow function coefficient (ffc) of the final blend was assessed using a Schulze ring shear tester (RST-XS.s, Jenike & Johanson, Tyngsboro, Massachusetts). In addition, Compressibility, Tabletability, Compactability (CTC) profiles of the final blend were generated on an MCC Presster compaction emulator (MCC, East Hanover, NJ) to assess the dependence of strain rate on compression properties. Methods for each measurement can be found in the appendix section A.4.

2.8. Tablet characterization {#s0100}
----------------------------

### 2.8.1. Disintegration {#s0105}

HLDF, benchmark and negative control tablets were evaluated for disintegration performance in a USP disintegration apparatus (ZT-71 disintegration tester, Erweka, Heusenstamm, Germany) according to the USP method ([@bb0045]). Tablets were placed one each inside of the six tubes within the basket-rack assembly. 750 ml of 0.01 N HCl (pH 2) maintained at 37 ± 2 °C was used as the immersion fluid.

### 2.8.2. *In vitro* dissolution performance {#s0110}

The rates and extents of dissolution and precipitation of the HLDF, benchmark and negative control tablets were measured using a custom Controlled Transfer Dissolution (CTD) apparatus. In the CTD apparatus, a drug product is administered in the stomach compartment. Disintegrated drug particles and drug in solution transit from the stomach compartment into the duodenum followed by the jejunum compartment at a user specified fluid emptying rate (See Fig. A1 in appendix section A.4 for a schematic of the apparatus). The CTD apparatus is based upon similar systems in the literature ([@bb0025]; [@bb0035]; [@bb0040]; [@bb0205]).

Dissolution testing was performed using two different gastric pH values since variation in gastric pH is known to impact solubility and dissolution of weakly basic drugs and enteric polymers ([@bb0125]) ([@bb0130]). The gastric pH values selected were representative of fasted humans (pH 2.0) and of fasted humans on a PPI (pH 6.0). The duodenal compartment pH was representative of fasted humans (pH 6.5) ([@bb0060]; [@bb0120]). Fluid compositions and testing parameters are shown in [Table 3](#t0015){ref-type="table"}). At the 100-mg tablet dose, erlotinib was dosed below saturation with respect to crystalline free base solubility at low gastric pH but supersaturated at high gastric pH. Erlotinib was supersaturated with respect to crystalline free base solubility in the duodenum and jejunum compartments for both experiments. For the low gastric pH experiments, concentration vs. time profiles were generated in all compartments using *in situ* UV fiber optic probes (Pion Rainbow™, Pion Inc., Billerica, MA). Second derivative detection at a wavelength range of 376--380 nm (stomach compartment) and 332--336 nm (duodenum/jejunum compartments) was used with a calibration range of 0--216 μg/ml. For the high gastric pH experiments, the detection wavelength range was consistent across all compartments at 332--336 nm using a calibration range of 0--65 μg/ml. Each CTD test was performed in duplicate. Area Under the Curve (AUC) values in the duodenum and jejunum compartments were calculated to compare performance as a function of gastric pH.Table 3Controlled Transfer Dissolution (CTD) experimental parameters.Table 3ParameterValueDose (mg)100Dosing volume (ml)240Dosing medium0.025% (w/w) FaSSIF powder in Milli-Q waterStomach pH2.0 or 6.0Stomach resting volume (ml)50Stomach resting and secretion medium0.01 N HCl + 34 mM NaCl (pH 2), 1e-06 N HCl + 34 mM NaCl (pH 6)Stomach secretion rate (ml/min)2Stomach fluid emptying rate half-life (mono-exponential, min)15Duodenum pH6.5Duodenum volume (ml)50Duodenum resting and secretion medium1% (w/w) FaSSIF powder[a](#tf0035){ref-type="table-fn"} in 134 mM phosphate, pH 6.5Jejunum pH6.5Jejunum mediumGastric + duodenum compositionJejunum volumeStarts at 0 & increases to 597 ml at 90 min[^7]

### 2.8.3. Additional tablet characterization {#s0115}

Friability and content uniformity testing were performed on HLDF tablets. See appendix section A.4 for methods.

3. Results and discussion {#s0120}
=========================

3.1. Drug and ASD characterization {#s0125}
----------------------------------

### 3.1.1. Erlotinib crystalline solubility {#s0130}

The equilibrium crystalline solubilities of erlotinib in pH 6.5 phosphate, pH 6.5 phosphate with 0.5% (w/w) FaSSIF powder, and pH 6.5 phosphate with 1% (w/w) FaSSIF powder at 37 °C can be found in [Table 1](#t0005){ref-type="table"}.

### 3.1.2. Powder X-Ray Diffraction (PXRD) {#s0135}

PXRD patterns from the ASDs after spray drying were compared to the sharp characteristic diffraction peaks of pure crystalline erlotinib. No diffraction peaks were detected in the ASDs indicating they were amorphous. Diffractograms are presented in Fig. A2 the appendix section A.6.

### 3.1.3. Scanning Electron Microscopy (SEM) {#s0140}

Morphology of crystalline erlotinib and representative ASDs prior to accelerated stability storage are presented in Fig. A3 in the appendix section A.7. As received, crystalline erlotinib has a plate-like crystal habit. Morphology of the ASDs included collapsed spheres or a mixture of collapsed spheres and fractured collapsed spheres. No crystalline material was observed along the surfaces of the ASDs.

### 3.1.4. Differential Scanning Calorimetry (DSC) {#s0145}

The T~m~ of the crystalline erlotinib free base (Form II) measured by DSC was 157 °C, with a heat of fusion of 139 J/g. The T~g~ of amorphous erlotinib measured by DSC had an onset temperature of 39 °C and a midpoint temperature of 42 °C.

Dry T~g~ versus drug loading for all ASDs and T~g~ versus RH for selected ASDs are shown in [Fig. 2](#f0010){ref-type="fig"} and [Fig. 3](#f0015){ref-type="fig"}, respectively. All ASDs demonstrated a single T~g~ suggesting a homogeneous phase of polymer and drug. Dry T~g~ at a given drug loading is higher for the Eudragit L100 compared to the HPMCAS-H ASDs. For example, the dry T~g~ of the 60/40 erlotinib/Eudragit L100 ASD is 106 °C, which is 51 °C higher than the HPMCAS ASD with equal active loading (60/40 erlotinib/HPMCAS-H; T~g~ = 55 °C). The more favorable T~g~ values of the Eudragit L100 compared to the HPMCAS-H ASDs at a given drug loading is mainly attributed to the higher T~g~ of Eudragit L100 compared to HPMCAS-H. However, factors such as intermolecular interactions between drug and polymer can also impact dispersion T~g~ ([@bb0105]; [@bb0140]).Fig. 2Glass transition temperature (T~g~) versus fraction drug in polymer (w/w) for Eudragit L100 (circles) and HPMCAS-H (squares) Amorphous Solid Dispersions (ASDs).Fig. 2Fig. 3Glass transition temperature (T~g~) versus percent relative humidity (% RH) for selected Eudragit L100 (circles) and HPMCAS-H (squares) Amorphous Solid Dispersions (ASDs). Dashed line represents the storage temperature for the accelerated physical stability studies.Fig. 3

The large difference in T~g~s between the Eudragit L100 and HPMCAS-H ASDs persists at increasing RH values. For example, at 75% RH the 60/40 erlotinib/Eudragit L100 ASD has a 43 °C higher T~g~ than the HPMCAS ASD with equivalent drug loading (71 °C vs. 28 °C, respectively). For all ASDs, T~g~ decreases with increasing RH with approximately the same slope, indicating that the ASDs are plasticized similarly by water. T~g~ values of selected ASDs and T~g~ versus RH for additional ASDs are presented in Fig. A4 in the appendix section A.8.

3.2. ASD physical stability {#s0150}
---------------------------

Erlotinib/Eudragit L100 ASDs at drug loadings up to and including 65% (w/w) remained stable throughout the 4-week study. ASD stability was indicated by 1) lack of sharp diffraction peaks in the PXRD, 2) lack of fusing and morphology changes in SEM micrographs 3) a single T~g~ without melting events in the DSC. At 75% drug loading, fibrous structures were observed in the micrographs after 1 week at 40 °C/75%RH. PXRD indicated characteristic Bragg diffraction peaks that matched a known crystalline form of erlotinib, confirming evidence of recrystallization. The T~g~ remained equivalent to the initial T~g~ of the sample and no crystallization was observed via DSC. However, a small endothermic peak was observed at 145 °C.

Benchmark ASDs comprising HPMCAS-H remained stable throughout the 4-week study for drug loadings up to and including 35% (w/w). However, at drug loadings of 50 and 60% (w/w), the benchmark ASDs showed crystallization after 1 week. SEM micrographs showed fusing of the particles and re-crystallization after 1 week for both the 50% and 60% ASDs. These observations were confirmed by evidence of sharp diffraction peaks in the XRD patterns of the 1-week samples. See appendix section A.9 for SEM micrographs, PXRD diffractograms and DSC thermograms of selected ASDs at 0 and 4 weeks.

Stability data indicated Eudragit L100 provided superior stability at higher drug loadings than the benchmark dispersion polymer HPMCAS-H (See [Table 4](#t0020){ref-type="table"} for summary of accelerated physical stability testing results.). The more favorable physical stability under stressed conditions of the Eudragit L100 compared to the HPMCAS-H ASDs is likely driven by the higher T~g~ of Eudragit L100 compared to HPMAS-H. For example, when equilibrated to the 75% RH storage condition, the T~g~s of the Eudragit L100 dispersions were all above the 40 °C storage temperature ([Fig. 3](#f0015){ref-type="fig"}). The stable 60% (w/w) and 65% (w/w) Eudragit L100 ASDs were 21 °C and 31 °C above the storage temperature, respectively, whereas the non-stable 75% (w/w) Eudragit L100 ASD was only 4 °C above the storage temperature. The stable 25% (w/w) and 35% (w/w) HPMCAS-H ASDs were both 7 °C above the storage temperature, whereas the non-stable 50% (w/w) and 60% (w/w) HPMCAS ASDs were 7 and 12 °C below the storage temperature, respectively. Previous studies have suggested that T~g~ -- T needs to be at least 50 °C for pure amorphous materials (e.g. pure drug) to ensure minimal molecular mobility ([@bb0260]) ([@bb0085]). For ASDs formulated with stabilizing polymers, T~g~ -- T values of 5--30 °C are often high enough to impart two-year stability, depending on drug and polymer properties, drug loading and water uptake ([@bb0065]) ([@bb0240]) ([@bb0255]) ([@bb0080]). The ASDs that remained stable after 4 weeks at 40 °C and 75% RH all had T~g~ -- T values within this range at 75% RH.Table 4Results of accelerated physical stability testing of Eudragit L100 and HPMCAS-H ASDs.Table 4Dispersion polymerDrug loading (weight%) in ASDResults after 4 weeks at 40 °C/75%RHEudragit L10025Stable (no change)50Stable (no change)60Stable (no change)65Stable (no change)75Unstable (fibrous structures after 1 week)HPMCAS-H25Stable (no change)35Stable (no change)50Unstable -- crystals after 1 week60Unstable -- crystals after 1 week

3.3. HLDF manufacturability {#s0155}
---------------------------

### 3.3.1. Clinical scale spray drying {#s0160}

Clinical scale spray drying resulted in desirable ASD morphology characterized by low aspect ratio particles and a lack of filaments as visualized using SEM ([@bb0180]). See Fig. A4 in the appendix section A.7 for the SEM image. Residual methanol present in the ASD after secondary drying was less than 200 ppm as assessed on four replicates using gas chromatography. This value is an order of magnitude below the maximum allowable concentration of 3000 ppm according to International Council for Harmonization (ICH) guidelines.

The spray solution solids loading was maximized to 3% (w/w) based upon the erlotinib solubility in methanol (2.2% (w/w)). At this solids loading spray drying throughput is comparable to what could be achieved for a lower drug loading erlotinib ASD. For example, while a 25/75 erlotinib/Eudragit L100 ASD could achieve an 8% (w/w) spray solution solids loading at a 2% (w/w) erlotinib loading, it would yield the same mass of amorphous erlotinib per unit time as the 65/35 erlotinib/Eudragit L100 ASD sprayed at 3% (w/w) solids loading, assuming comparable spray solution flow rate and yield. In this study, ASD yield assessed prior to secondary drying was high (96%).

### 3.3.2. Downstream tablet manufacturing {#s0165}

HLDF tablets manufactured on the roller compactor and rotary tablet press met friability, weight uniformity and assay-based content uniformity specifications (See appendix section A.10).

The HLDF formulation is unique compared to a typical spray dried ASD formulation in that a small particle size polymer (HPMCAS-HF) is incorporated into the granulation. Whereas typical intra-granular excipients such as microcrystalline cellulose and lactose have mean particle diameters of at least 50 μm, HPMCAS-HF has a mean particle diameter of 5 μm ([@bb0185]). Incorporation of this small particle size excipient during roller compaction was deemed risky due to a potential for poor flowability and excessive fines. Despite this risk, roller compaction of the HLDF intra-granular blend was successful, resulting in good compaction, minimal sticking, minor bypass and low fines. The measured granule size distribution was in line with distributions of conventional ASD granulations manufactured in-house (data not shown).

Roller compaction improved bulk density, tapped density and flowability. Average bulk powder and flow properties are included in [Table 5](#t0025){ref-type="table"}. Flowability measurements were indicative of the successful tableting on the Korsch XL 100 rotary tablet press at 20 and 50 rpm. Avicel PH 102 can serve as a benchmark for assessing whether flowability is adequate for successful tableting on a high-speed tablet press ([@bb0195]). Avicel PH 102 has a Carr\'s Index of 25.8%, and an ff~c~ of 6.1 at a 1 kPa pre-consolidation stress and 20% RH ([@bb0195]). Carr\'s Index of the extra-granular blend in this study (22%) was superior to that of Avicel PH 102. However, the ff~c~ (4.3) fell below the criterion. While flowability was still acceptable for rotary tableting in this study, flow properties of the extra-granular blend could be further improved through formulation optimization to facilitate manufacturing at higher speeds.Table 5Average bulk powder and flow properties for intra- and extra-granular novel architecture blends.Table 5BlendBulk density (g/cm^3^)Tapped density (g/cm^3^)True density (g/cm^3^)Carr\'s index (%)ff~c~Intra-granular0.220.361.32538N/AExtra-granular (final blend)0.440.561.332224.3

The rotary tablet press and the Presster compaction emulator demonstrated excellent Compressibility, Tabletability and Compactability (CTC) of the extra-granular blend. See [Table 6](#t0030){ref-type="table"} for Compression Pressure (CP) and Solid Fraction (SF) at each TS produced on the rotary tablet press. CTC profiles generated using the compaction emulator are shown in [Fig. 4](#f0020){ref-type="fig"}. See appendix section A.10 for analysis of TS and CP at SF = 0.85. The compaction pressures needed to achieve a TS of 2 MPa on the rotary press and compaction emulator were low and therefore reasonable for manufacturing equipment. A tablet TS of 2 MPa is commonly targeted to achieve strong tablets meeting the USP friability standard ([@bb0150]; [@bb0160]). The CP needed to achieve TS = 2 MPa on the compaction emulator at 10 ms (\< 60 MPa) was only \~20 MPa higher than what was needed to reach TS = 2 MPa for Avicel PH 102 at 8 ms on the same equipment, as measured by Tye and coworkers ([@bb0225]). While an effect of strain rate was observed at higher CP when comparing the 10 ms and 100 ms dwell times, this result was not practically relevant since lower CPs are needed to achieve TS = 2 MPa. The SF needed to achieve TS = 2 MPa (\~0.76) measured on the compaction emulator fell between that of Avicel PH 102 (\~0.55) and the common tableting excipient, lactose monohydrate (0.80), as measured by Tye and coworkers ([@bb0225]).Table 6Tableting mechanical properties achieved using Korsch XL 100 (3/8" SRC tooling), 14 MPa pre-compression pressure.Table 6Compression pressure (MPa)Tensile strength (MPa)Solid fractionTurret speed (rpm)/dwell time (ms)732.00.7820 rpm/81772.00.7850 rpm/32531.20.7320 rpm/81872.80.8120 rpm/81Fig. 4Compressibility Tabletability Compactability (CTC) profiles generated using the Presster™ compaction emulator at 10 ms (closed circles) and 100 ms (open circles) dwell times.Fig. 4

3.4. Tablet performance {#s0170}
-----------------------

Average disintegration times are listed in [Table 7](#t0035){ref-type="table"}. HLDF tablets produced using the roller compactor and rotary tablet press disintegrated in less than 2.5 min across the TS range of 1.2 -- 2.8 MPa, with an average disintegration time of 1.1 min at TS = 2 MPa. Disintegration time increased with an increase in TS. Benchmark tablets disintegrated in less than 1 min. Disintegration testing was not formally performed on each tablet at pH 6 (elevated gastric condition) but demonstrated rapid (\< 2 min) visual disintegration during CTD testing at those conditions.Table 7Disintegration testing results.Table 7Tablet typeTablet tensile strength (MPa)Turret speed (rpm)Disintegration time, min\
average (standard deviation), *n* = 3Benchmark2N/A (manual press)0.93 (0.04)Negative control2N/A (manual press)Did not measureHLDF2.0201.1 (0.13)HLDF1.2200.5 (0.02)HLDF2.8202.4 (0.04)HLDF2.0501.1 (0.12)

*In vitro* dissolution testing demonstrated similar performance between the HLDF tablet and the benchmark tablet at both low (pH 2.0) and high (pH 6.0) gastric pH, whereas the negative control tablet showed inferior performance at high gastric pH due to more rapid crystallization in the duodenum and jejunum. CTD results are shown in [Fig. 5](#f0025){ref-type="fig"} and [Fig. 6](#f0030){ref-type="fig"} for the low gastric pH and high gastric pH tests, respectively. Tabulated data are shown in the appendix section A.10. At low gastric pH, the HLDF and benchmark tablets had duodenal AUC~0--90~ values 1.8 times greater than the negative control tablet. At high gastric pH, the HLDF and benchmark tablets had duodenal AUC~0--90~ values 2.8 times greater than the negative control tablet. At high gastric pH, the HLDF tablet shows less gastric release than the benchmark tablet, which can be attributed to the lower solubility of erlotinib at pH 6 compared to pH 2. Total AUC in the duodenum and jejunum at high gastric pH was 70% of that at low gastric pH for both the HLDF and benchmark, compared to 60% for the negative control.Fig. 5Concentration time profiles in the stomach, duodenum and jejunum compartments of the Controlled Transfer Dissolution (CTD) test at low (pH 2) gastric pH for High Loaded Dosage Form (HLDF), benchmark and negative control tablets.Fig. 5Fig. 6Concentration time profiles in the stomach, duodenum and jejunum compartments of the Controlled Transfer Dissolution (CTD) test at high (pH 6) gastric pH for High Loaded Dosage Form (HLDF), benchmark and negative control tablets.Fig. 6

HLDF tablets showed equivalent *in vitro* performance in the CTD test, while reducing tablet mass by 40% relative to the benchmark tablet. The HLDF tablet significantly outperformed the negative control by delaying precipitation, due to incorporation of HPMCAS-H external to the ASD. External HPMCAS-H was able to provide similar sustainment of supersaturation of erlotinib in both the HLDF and benchmark tablets at both gastric conditions (pH 2.0 and pH 6.0), suggesting that the CSP does not require incorporation into the spray dried ASD intermediate itself, but can be successfully distributed into the final dosage form. Additionally, the HLDF tablet provided similar performance with a lower amount of HPMCAS-H (1:1 erlotinib:HPMCAS-H vs. 1:1.85 erlotinib:HPMCAS-H in benchmark). This information suggests that incorporating the HPMCAS-H outside of the ASD allows for composition optimization without negatively impacting physical stability or manufacturability. This flexibility allows a formulator to optimize the level of CSP for bioperformance.

Interestingly, differentiation was observed in gastric dissolution rate at elevated gastric pH between the HLDF and benchmark tablets. This result is likely attributed to the "sharper" solubility versus pH profile of Eudragit L100 versus HPMCAS-H, specifically around the pH where both polymers are intended to dissolve. Eudragit L100 has a significantly higher acidic content (ca. 5.6 mM acid/g polymer) compared to HPMCAS-H (0.64 mM acid/g polymer),[1](#fn0005){ref-type="fn"} providing potential benefit in limiting the release of drug at elevated gastric pH (up to \~pH 6), and therefore decreasing the risk of gastric precipitation to a lower energy drug form. Though gastric precipitation was not observed for erlotinib in this study, it is a known risk for poorly water soluble weakly basic drugs that are a focus of the HLDF architecture.

The CTD data presented supports the hypothesis that the HLDF architecture should perform similarly to the lower loaded benchmark tablets and outperform the high loaded negative control tablets. This result would be expected to occur particularly at high doses, where absorption is driven predominately by the ability to maintain high (supersaturated) drug concentrations in the intestine.

4. Conclusions {#s0175}
==============

The current study demonstrates a new high drug loading dosage form architecture for ASDs of rapidly crystallizing poorly soluble drugs. This "HLDF" architecture strategically combines two different polymers, one inside and one outside the ASD, to optimize solubilization performance, physical stability and manufacturability. Using this architecture versus using a single dispersion polymer in the ASD to maintain physical stability and sustain supersaturation can allow equivalent *in vitro* performance while reducing dosage form size. Here we demonstrate the HLDF architecture using the low T~g~, rapidly crystallizing drug, erlotinib. For this model drug, using Eudragit L100 as the dispersion polymer and HPMCAS-H as a concentration sustaining polymer (CSP) granulated with the ASD reduced tablet mass by 40% compared to using HPMCAS-H as both the dispersion polymer and the CSP. Physical stability and *in vitro* dissolution performance were comparable for the HLDF architecture and traditional benchmark approach, and excellent manufacturability of the HLDF architecture was demonstrated. This work presents *in vitro* results, demonstrating a promising strategy for decreasing tablet size and/or number of dosage units for drug candidates requiring an amorphous form of the drug to achieve good *in vivo* performance.
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Eudragit L100 acid content calculated from average of 300--330 mg KOH/g dry L100 reported in Evonik technical bulletin. HPMCAS acid content calculated from the succinate assay reported in the certificates of analysis for 17 lots of Shin-Etsu HPMCAS-H.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ijpx.2020.100042>.

[^1]: From reference ([@bb0220]) at 25 °C.

[^2]: Erlotinib free base Form II. Measured in house.

[^3]: From reference (Williams et al., 2018).

[^4]: Measured in house.

[^5]: The majority of excipients (including external HPMCAS-H for the HLDF tablet) are granulated with the ASD. Additional excipients are blended with the granules and the final blend is compressed into tablets. Detailed compositions can be found in Table A.1. in appendix section A.1.

[^6]: Tableting excipients include Avicel PH 101, lactose monohydrate 310, ac-di-sol, cab-o-sil M5P and magnesium stearate.

[^7]: 1% (w/w) FaSSIF powder is equivalent to 13.4 mM sodium taurocholate. Using these resting and secretion volumes, the range in FaSSIF observed in the duodenal compartment ranges from 1% (w/w) to 0.2% (w/w).
